MeMed’s Mission: Pressing Its Fingerprint Against AMR
Executive Summary
Approved in Europe and just given the US green light, MeMed is making waves in the fight against antimicrobial resistance using advanced "host response" technology. Its CEO talks to In Vivo about strategy, commercialization and earning the right to fantasize.
You may also be interested in...
MeMed Secures $93M Financing To Commercialize Diagnostics Platform
The company will use the money to fund its US commercialization strategy and continue to develop its host response-based product pipeline.
Point Of Care Diagnostics In 2022: New Technology But Old Problems
Following a busy year for point of care diagnostics, the industry is facing a period of consolidation. The drive for new technologies is being countered by regulatory and financial issues.
Muvon Therapeutics: The Road To Expansion
Deana Mohr, Muvon Therapeutics’ co-founder and chief executive, and one of In Vivo’s 2022 Rising Leaders, aspires to push the organization to the next level by scaling up the company and developing its therapies into marketable products.